Vegetal based Oncolytic, Oncostatic and Anti-herpes.
Chahina ® is an active principle obtained from Thuja.
Action Mechanism
Clinical studies have shown a hormone regulating effect at the Hypophysis Core level, interfering with the nutrition, growth, and development as well as the proliferation of neoplastic cells by blocking the hormonal diffusion to the tissue, contributing to the lysis and the expulsion of nucleoproteins and neoplastic endotoxins.
It is an extremely effective antiviral agent against Herpes Simplex virus I and II (HSV-1 and HSV-2). Stimulates the immunologic function.
Uses

• Malignant hematologic illness: Acute and chronic leukemia, Hodgkin’s Lymphoma, non-Hodgkin’s lymphoma, Lymphosarcoma.
• Solid Tumors: Retinoblastoma, Astrocytoma, Tongue Aden carcinoma, Bronchogenic, Gastric, Colon, Rectum, Renal and Bladder carcinoma, Hepatocellular carcinoma, Bile Duct cancer, cervix, uterine and ovary osteosarcoma, etc.
• Hormone-dependent: Endometruim, cervix, ovary, prostatic and testicle carcinoma.
• Benign Tumors: Lipoma, fibrocystic mastopathy, mammary adenosis, myomatosis, warts. Thrombotic thrombocytopenic purpura without previous splenectomy or corticotherapy.
•  Herpetic processes of any sign: indicated on the treatment for initial infections caused by the Herpes Simplex virus on the skin and mucous, even on Genital Herpes, and Zoster Herpes initial or recurring in patients either immunocompromised or non-immunocompromised, Chahina ® has shown a remarkable effect over pain on the acute phase of Herpes.
• On Postherpetic Neuritis a positive answer has been obtained over pain with Chahina ® treatment.

After numerous toxicology tests, Chahina ® has been proven to be a highly nontoxic pharmaceutical due to its vegetal base. It does not cause myelosuppresion.

Contraindications
The experimentation on animals has not shown teratogenic effects or genetic change after use, human tests have not shown these effects either although the use during pregnancy and lactation periods is responsibility of the treating physician.

Interaction with other pharmaceuticals
The use of empirical treatments (leaf or root teas, etc), as well as hormonal, steroid, anti-inflammatory treatments should be avoided since the interaction with these can diminish, eliminate or block the absorption or action of Chahina ®.
In contrast to cytotoxic agents that need to be used only by Oncology specialized physicians due to undesirable effects such as myelosuppresion and toxicity, Chahina ® can be managed by physicians from any field since it DOESN’T have any secondary or irreversible effects; hospitalization or close watch on the patient is not necessary during treatment.
Chahina ® can be administered on patients who have recently received radiotherapy or cytotoxic agents since the treatment doesn’t present any antagonism.

Secondary Reactions
Some allergies and nausea have been occasionally shown at the beginning of the treatment; these disappear after continuing with the treatment and also ingesting it after meals.

Other symptoms
During the treatment some viscose sialorrhea, gelatinous looking secretions coming out of any excretory system way, as well as the expulsion of the necrotic neoplastic tissue on some patients, polyarthralgia, and urinary sedimentation; this profile is shown due to the excretion of nucleoproteins and endotoxins from the necrotic neoplastic tissue resulting from the medication.

Presentation
15 ml Dropper
Each milliliter contains
Thuja TM – 0.1 ml
Carrier q.s. – 1.0 ml
Reg. SSA: 005H90SSA – Aut. I.P.P. BERH-4264/97 

Vein wall regenerator, stimulant of the excretory system for the elimination of nucleoproteins and endotoxins of oncologic etiology.
Circulan® is a vegetal based pharmaceutical obtained from Rhus toxicodendrum, researched and developed by Laboratorios Orizaba.
Action Mechanism
It is an anatophysiologic regenerator of the circulatory system and accelerates the blood flow speed and increases arterial terminal irrigation providing better tissue nutrition, restructuring injured vein walls and increasing the capilovascular resistance and the venous tone directly through the vascular tunic. It also has been observed that Circulan® acts as a stimulant for the elimination of tumor endotoxins in the neoplastic processes throughout the excretory system.
Uses

• Hemiplegia and sequels of brain vascular disease.
• Senile sclerosis, diabetic retinopathy.
• Peripheral venous insufficiency.
• Varicose veins, ulcers, hemorrhoids, post-phlebitic sequels.
• Venous wall injuries: Atherosclerosis, aneurisms, atheromas.
• Vasculodermal injuries, chronic venous insufficiency: Varicose complex, chronic eczema due to venous stasis.
• At the peripheral level, it regenerates the inner tissue of the venous vessels greatly improving blood flow WITHOUT dilating the vessels.

Neoplastic Processes
Combined with Chahina®, a favorable therapeutic result is obtained to stimulate the elimination of tumor nucleoproteins and endotoxins, whatever their etiology and location.

Contraindications
The experimentation on animals has not shown teratogenic effects or genetic change after use, human tests have not shown these effects either although the use during pregnancy and lactation periods is responsibility of the treating physician.

Secondary Reactions
Some gastralgia can occasionally occur; it can be reduced by adding more water to the pharmaceutical or by drinking some milk. Burning of the veins can occur depending on the severity of the injury. These symptoms will start disappearing after continuing the treatment.

Method of Administration
Oral and Topical
Presentation
15 ml Dropper
Each milliliter contains
Rhus Toxicodrndrum TM – 0.1 ml
Carrier q.s. – 1.0 ml
Reg. SSA: 004H90SSA – Aut. I.P.P. BERH-4264/97

Glitrosan® is a vegetal based pharmaceutical.
Action Mechanism
Pituitary hormone-regulator; stimulates the pancreatic cells for insulin production and storage.
Uses

• Diabetes Mellitus either insulin dependent or non-insulin dependent (type I and II).

Interaction with other pharmaceuticals
The use of multivitamins and empirical pharmaceuticals (leaf, root teas, etc) should be excludes since they can inhibit the absorption of Glitrosan®.
The use of hypoglycemics combined with Glitrosan® does not accelerate response to the treatment or create an antagonism with it. At the beginning of the treatment, the clinic evolution of the patient will be evaluated and gradually the use of hypoglycemics will be reduced.
With insulin dependent patients the insulin will be reduced gradually depending on each patient’s response to the pharmaceutical.
Glitrosan® is not hypoglycemic medication, therefore it DOESN’T decrease the glucose; by stimulating the pancreatic function, the glucose decrease comes as a natural response to the function. An increase of glucose in the urine will be observed but will NOT be a decompensation of the medical profile.
Recommendation
The treatment with Glitrosan® should be supported by a balanced diet and physical exercise.
Contraindications
As a diabetic ketoacidosis. The use on pregnant women is under the responsibility of the treating physician.

Method of Administration
Oral
Presentation
15 ml Dropper
Each milliliter contains
Thuja T.M. – 0.05 ml
Rhus Toxicodrndrum TM – 0.05 ml
Carrier q.s. – 1.0 ml
Reg. SSA: 044H96SSA – Aut. I.P.P. AERH-34685/97

Virtusan® is a non hormonal, vegetal based anti-rheumatic. 
Action Mechanism
Anti-rheumatic of osteoarticular action.
Uses
Intra-joint diseases of unknown etiology:

• Rheumatoid arthritis, Ankylosing spondylitis (Enf. Marie Strumper)
• Degenerative arthropathy
• Osteoporosis
• Gout

Interaction with other pharmaceuticals
According to the clinical observations, the interaction of Virtusan® with corticosteroids and common anti-inflammatory medicine decreases its effectiveness. During the first weeks of the Virtusan® treatment some joint pain can be observed together with an increase of joint mobility; if the pain is intense, some analgesics such as pyrazolone and salicylates can be introduced.

Contraindications
The experimentation on animals has not shown teratogenic effects or genetic change after use, human tests have not shown these effects either although the use during pregnancy and lactation periods is responsibility of the treating physician. The dosage and tolerance for use of underage people has not been determined.

Method of Administration
Oral and Topical
Presentation
15 ml Dropper
Each milliliter contains
Salix Alba T.M. – 0.01ml
Thuja T.M. – 0.01 ml
Rhus Toxicodrndrum TM – 0.08 ml
Carrier q.s. – 1.0 ml
Reg. SSA: 044H96SSA
Reg. SSA: 037H96SSA– Aut. IPP AERH-3468/97

Chasal ® is a vegetal based pharmaceutical
Effective for the prevention and elimination of allergic profiles due to its immune system characteristics by potencializing it in two ways. Immunologic Action: Blocking the alteration at the immune level and increasing its response; Antiviral action: Interfering the cycle of the virus and prohibiting its replication as well as inhibiting histaminic reactions.
Uses

• Bronchial asthma
• Allergic Bronchitis

The pharmaceutical does not act on acute allergic profiles, if an infection exists during treatment it should be treated independently. On allergic asthma profiles, the crisis will diminish until they disappear. CH-AS ® prevents asthmatic profile recurrence.

Interaction with other pharmaceuticals
The use of empirical treatments (leaf or root teas, etc), as well as hormonal, steroid, anti-inflammatory treatments and multivitamins can modify the absorption and its action at the pituitary level as a hormone regulator, therefore the use of them should be avoided during treatment.

Contraindications
The experimentation on animals has not shown teratogenic effects or genetic change after use, human tests have not shown these effects either although the use during pregnancy and lactation periods is responsibility of the treating physician.

Method of Administration
Oral
Presentation
15 ml Dropper
Each milliliter contains
Turpentine T.M. – 0.01ml
Thuja T.M. – 0.03 ml
Rhus Toxicodrndrum TM – 0.06 ml
Carrier q.s. – 1.0 ml
Reg. SSA: 024H96SSA– Aut. IPP AERH-34684/97